Informed Decision Making in Advanced Non-Small Cell
Lung Cancer (NSCLC): Expert Strategies for
Individualized Treatment

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from March 10, 2018 to March 31, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AstraZeneca, Genentech, Lilly USA LLC, and Novartis Pharmaceuticals

Non-Small Cell Lung Cancer (NSCLC) is often diagnosed at an advanced stage, and despite progress in early detection and treatment, prognosis is poor. Historically, treatment has included a variety of modalities such as surgery, chemotherapy, and radiotherapy. The recent use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer. As more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets. These recently approved agents could help increase prognosis and quality of life in NSCLC patients. In addition, guidelines from the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) have been updated to incorporate a section on maintenance therapy in the management of advanced NSCLC.

Upon Completion of this activity, participants will be able to:

  • Analyze safety, efficacy and tolerability data in current and emerging treatments in the management of advanced non-small cell lung cancer (NSCLC)

  • Examine recent clinical data and expert updated strategies on novel therapies for the first-line treatment of advanced squamous NSCLC

  • Explore the roles of biopsy, histology, and molecular testing in subtyping and treatment decision-making in advanced NSCLC

  • Identify patient and clinical factors used to individualize therapy and guide first-line and maintenance therapy selection in advanced NSCLC

  • Evaluate options in the second line and beyond for patients with advanced NSCLC in the context of patient characteristics and prior lines of therapy

  • Summarize strategies to proactively plan for and manage treatment-related, adverse events in patients with advanced NSCLC

Faculty: James Jett, MD
Professor of Medicine, Emeritus
University of Colorado-Denver Hospital


Dr. Jett self-manages stock with and serves as a consultant with Oncimmune LLC. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
AstraZeneca, Genentech, Lilly USA LLC, and Novartis Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue